Cargando…
The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-cont...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Milan
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356470/ https://www.ncbi.nlm.nih.gov/pubmed/22430431 http://dx.doi.org/10.1007/s10194-012-0428-7 |